PT3237418T - Compostos de triazolopirimidina e suas utilizações - Google Patents

Compostos de triazolopirimidina e suas utilizações

Info

Publication number
PT3237418T
PT3237418T PT15820637T PT15820637T PT3237418T PT 3237418 T PT3237418 T PT 3237418T PT 15820637 T PT15820637 T PT 15820637T PT 15820637 T PT15820637 T PT 15820637T PT 3237418 T PT3237418 T PT 3237418T
Authority
PT
Portugal
Prior art keywords
triazolopyrimidine compounds
triazolopyrimidine
compounds
Prior art date
Application number
PT15820637T
Other languages
English (en)
Portuguese (pt)
Inventor
Man Chan Ho
Justin Gu Xiang-Ju
Huang Ying
Li Ling
Mi Yuan
Qi Wei
Sendzik Martin
Sun Yongfeng
Wang Long
Yu Zhengtian
Zhang Hailong
Yue Ji (Jeff) Zhang
Zhang Man
Zhang Qiong
Zhao Kehao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PT3237418T publication Critical patent/PT3237418T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT15820637T 2014-12-23 2015-12-21 Compostos de triazolopirimidina e suas utilizações PT3237418T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23

Publications (1)

Publication Number Publication Date
PT3237418T true PT3237418T (pt) 2019-05-23

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
PT15820637T PT3237418T (pt) 2014-12-23 2015-12-21 Compostos de triazolopirimidina e suas utilizações

Country Status (40)

Country Link
US (5) US10220036B2 (cg-RX-API-DMAC7.html)
EP (1) EP3237418B1 (cg-RX-API-DMAC7.html)
JP (1) JP6736559B2 (cg-RX-API-DMAC7.html)
KR (1) KR102534028B1 (cg-RX-API-DMAC7.html)
CN (1) CN107108637B (cg-RX-API-DMAC7.html)
AU (1) AU2015370524B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017010354B8 (cg-RX-API-DMAC7.html)
CA (1) CA2969090C (cg-RX-API-DMAC7.html)
CL (1) CL2017001572A1 (cg-RX-API-DMAC7.html)
CO (1) CO2017005992A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170285A (cg-RX-API-DMAC7.html)
CY (1) CY1121901T1 (cg-RX-API-DMAC7.html)
DK (1) DK3237418T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2017000149A (cg-RX-API-DMAC7.html)
EA (1) EA032416B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP17047153A (cg-RX-API-DMAC7.html)
ES (1) ES2722048T3 (cg-RX-API-DMAC7.html)
GT (1) GT201700146A (cg-RX-API-DMAC7.html)
HR (1) HRP20190805T1 (cg-RX-API-DMAC7.html)
HU (1) HUE043060T2 (cg-RX-API-DMAC7.html)
IL (1) IL252135B (cg-RX-API-DMAC7.html)
JO (1) JO3489B1 (cg-RX-API-DMAC7.html)
LT (1) LT3237418T (cg-RX-API-DMAC7.html)
ME (1) ME03385B (cg-RX-API-DMAC7.html)
MX (1) MX375970B (cg-RX-API-DMAC7.html)
MY (1) MY186837A (cg-RX-API-DMAC7.html)
NZ (1) NZ731664A (cg-RX-API-DMAC7.html)
PE (1) PE20171307A1 (cg-RX-API-DMAC7.html)
PH (1) PH12017501016A1 (cg-RX-API-DMAC7.html)
PL (1) PL3237418T3 (cg-RX-API-DMAC7.html)
PT (1) PT3237418T (cg-RX-API-DMAC7.html)
RS (1) RS58679B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201703880VA (cg-RX-API-DMAC7.html)
SI (1) SI3237418T1 (cg-RX-API-DMAC7.html)
SV (1) SV2017005472A (cg-RX-API-DMAC7.html)
TN (1) TN2017000204A1 (cg-RX-API-DMAC7.html)
TW (1) TWI694076B (cg-RX-API-DMAC7.html)
UA (1) UA120945C2 (cg-RX-API-DMAC7.html)
UY (1) UY36462A (cg-RX-API-DMAC7.html)
WO (1) WO2016103155A1 (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA032416B1 (ru) * 2014-12-23 2019-05-31 Новартис Аг Соединения триазолопиримидина и их применения
US11786533B2 (en) 2016-06-01 2023-10-17 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
ES2798424T3 (es) * 2016-06-20 2020-12-11 Novartis Ag Compuestos de triazolopiridina y usos de estos
EP3472166A1 (en) 2016-06-20 2019-04-24 Novartis AG Imidazopyrimidine compounds useful for the treatment of cancer
JP7042812B2 (ja) * 2016-06-20 2022-03-28 ノバルティス アーゲー トリアゾロピリミジン化合物の結晶形態
TN2019000010A1 (en) 2016-07-12 2020-07-15 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
CA3051054A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Pyridine compounds as allosteric shp2 inhibitors
CA3051206A1 (en) 2017-01-23 2018-07-26 Revolution Medicines, Inc. Bicyclic compounds as allosteric shp2 inhibitors
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
KR20190129851A (ko) * 2017-03-16 2019-11-20 지앙수 헨그루이 메디슨 컴퍼니 리미티드 헤테로아릴[4,3-c]피리미딘-5-아민 유도체, 이의 제조 방법 및 이의 의학적 용도
CN110944628A (zh) 2017-06-02 2020-03-31 Epizyme股份有限公司 使用ezh2抑制剂治疗癌症
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
RU2020115095A (ru) 2017-10-12 2021-11-12 Революшн Медсинз, Инк. Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
MX2020006273A (es) 2017-12-15 2020-09-14 Revolution Medicines Inc Compuestos policiclicos como inhibidores alostericos de shp2.
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
EP3743416B1 (en) * 2018-01-23 2023-03-15 Basf Se Halogenation of pyridine derivatives
HUE059536T2 (hu) * 2018-01-31 2022-11-28 Mirati Therapeutics Inc PRC2-inhibitorok
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
CN113272303B (zh) * 2018-11-30 2024-09-17 上海拓界生物医药科技有限公司 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
CN114144230B (zh) 2019-03-15 2024-04-23 弗尔康医疗公司 作为eed和prc2调节剂的大环唑并吡啶衍生物
KR102875195B1 (ko) * 2019-04-03 2025-10-22 케미테라스, 인크. 티민 핵산 염기를 베이스로 하는 트리아졸로피리미딘류 및 그 제조 방법
EP3959214A1 (en) * 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
EP3969639B1 (en) 2019-05-13 2025-03-12 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
CN114269748A (zh) * 2019-06-05 2022-04-01 米拉蒂医疗股份有限公司 作为用于治疗癌症的PRC2抑制剂的咪唑并[1,2-c]嘧啶衍生物
US20220305021A1 (en) * 2019-06-05 2022-09-29 Athenex, Inc. Methods of treating and/or preventing psoriasis
AU2020315401B2 (en) 2019-07-16 2025-05-22 The Regents Of The University Of Michigan Imidazopyrimidines as EED inhibitors and the use thereof
CN112409385B (zh) * 2019-08-22 2024-08-13 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
WO2021057853A1 (en) * 2019-09-26 2021-04-01 Novartis Ag Aza-quinoline compounds and uses thereof
CN118652256A (zh) * 2019-11-01 2024-09-17 上海科技大学 Eed抑制剂及其制备方法和用途
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
CN113636993B (zh) * 2020-05-11 2022-08-19 苏州亚盛药业有限公司 (5-氟-2,3-二氢苯并呋喃-4-基)甲胺或其盐的制备方法及其中间体
JP2023527823A (ja) * 2020-05-28 2023-06-30 ノバルティス アーゲー ＰＲＣ２媒介性疾患又は障害の治療に使用するためのＮ－（（５－フルオロ－２，３－ジヒドロベンゾフラン－４－イル）メチル）－８－（２－メチルピリジン－３－イル）－［１，２，４］トリアゾロ［４，３－ｃ］ピリミジン－５－アミン又はその薬学的に許容できる塩の投与計画
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
KR100609800B1 (ko) 1998-12-16 2006-08-09 워너-램버트 캄파니 엘엘씨 Ｍｅｋ 저해제를 사용한 관절염 치료 방법
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
YU2503A (sh) 2000-07-19 2006-05-25 Warner-Lambert Company Oksigenovani estri 4-jodo fenilamino benzhidroksamskih kiselina
SE519662C2 (sv) 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
AU2002357667A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) * 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
IL163711A0 (en) 2002-03-08 2005-12-18 Eisai Co Ltd Macrocyclic compounds useful as pharmaceuticals
TWI350285B (en) 2002-03-13 2011-10-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
JP2007524596A (ja) 2003-02-28 2007-08-30 トランスフォーム・ファーマシューティカルズ・インコーポレイテッド 共結晶医薬組成物
WO2005005601A2 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
US7563589B2 (en) 2004-06-01 2009-07-21 The University Of North Carolina At Chapel Hill Reconstituted histone methyltransferase complex and methods of identifying modulators thereof
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
EP1912636B1 (en) 2005-07-21 2014-06-25 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2007114896A2 (en) 2006-03-31 2007-10-11 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2008083251A2 (en) 2006-12-27 2008-07-10 Usc Stevens - University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
EP2426108B1 (en) 2007-08-29 2016-08-10 MethylGene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
PE20090678A1 (es) 2007-09-12 2009-06-27 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos y los metodos de uso
WO2009055730A1 (en) 2007-10-25 2009-04-30 Genentech, Inc. Process for making thienopyrimidine compounds
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
US8895526B2 (en) 2009-03-27 2014-11-25 Cold Spring Harbor Laboratory Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
CN102970869B (zh) * 2010-05-07 2014-07-16 葛兰素史密斯克莱有限责任公司 吲哚
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
US20140213475A1 (en) 2011-07-14 2014-07-31 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
US9730925B2 (en) 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
HUE042271T2 (hu) 2012-03-12 2019-06-28 Epizyme Inc Emberi EZH2 inhibitorai és azok alkalmazási eljárásai
US20150291598A1 (en) 2012-11-19 2015-10-15 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
EP2970306A4 (en) * 2013-03-15 2016-08-03 Epizyme Inc SUBSTITUTED 6.5-CONDENSED BICYCLIC HETEROARYL COMPOUNDS
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
AU2015217152A1 (en) 2014-02-11 2016-08-11 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
ES2719736T3 (es) 2014-11-14 2019-07-12 Basf Se Bencilpropargiléter como inhibidores de la nitrificación
PL3033944T3 (pl) 2014-12-16 2018-07-31 Omya International Ag Węglan wapnia do ochrony roślin
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
EA032416B1 (ru) * 2014-12-23 2019-05-31 Новартис Аг Соединения триазолопиримидина и их применения

Also Published As

Publication number Publication date
AU2015370524A1 (en) 2017-06-01
CA2969090C (en) 2023-05-02
KR102534028B1 (ko) 2023-05-19
PL3237418T3 (pl) 2019-07-31
EA201791420A1 (ru) 2017-10-31
CN107108637A (zh) 2017-08-29
IL252135A0 (en) 2017-07-31
MX2017008529A (es) 2017-10-25
EA032416B1 (ru) 2019-05-31
CL2017001572A1 (es) 2018-01-12
PE20171307A1 (es) 2017-09-05
DOP2017000149A (es) 2017-07-15
GT201700146A (es) 2019-06-12
NZ731664A (en) 2024-02-23
KR20170095882A (ko) 2017-08-23
BR112017010354B1 (pt) 2022-09-20
RS58679B1 (sr) 2019-06-28
WO2016103155A1 (en) 2016-06-30
BR112017010354B8 (pt) 2022-10-18
CY1121901T1 (el) 2020-10-14
ECSP17047153A (es) 2019-02-28
SV2017005472A (es) 2018-06-12
SI3237418T1 (sl) 2019-06-28
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
IL252135B (en) 2020-06-30
PH12017501016B1 (en) 2017-12-11
LT3237418T (lt) 2019-05-10
US20230033320A1 (en) 2023-02-02
US20160176882A1 (en) 2016-06-23
TW201629065A (zh) 2016-08-16
US11207325B2 (en) 2021-12-28
US20170348312A1 (en) 2017-12-07
ES2722048T3 (es) 2019-08-07
EP3237418A1 (en) 2017-11-01
JP6736559B2 (ja) 2020-08-05
EP3237418B1 (en) 2019-01-30
DK3237418T3 (da) 2019-05-13
CA2969090A1 (en) 2016-06-30
UY36462A (es) 2016-07-29
MY186837A (en) 2021-08-25
SG11201703880VA (en) 2017-07-28
JO3489B1 (ar) 2020-07-05
CO2017005992A2 (es) 2017-10-20
HUE043060T2 (hu) 2019-07-29
MX375970B (es) 2025-03-06
US9580437B2 (en) 2017-02-28
JP2018500342A (ja) 2018-01-11
CR20170285A (es) 2017-08-21
US20200323859A1 (en) 2020-10-15
TN2017000204A1 (en) 2018-10-19
ME03385B (me) 2020-01-20
US11931363B2 (en) 2024-03-19
BR112017010354A2 (pt) 2017-12-26
UA120945C2 (uk) 2020-03-10
PH12017501016A1 (en) 2017-12-11
US10220036B2 (en) 2019-03-05
AU2015370524B2 (en) 2018-11-01
HRP20190805T1 (hr) 2019-06-28
CN107108637B (zh) 2019-10-29

Similar Documents

Publication Publication Date Title
IL252135A0 (en) Triazolopyrimidine compounds and their uses
LT3215147T (lt) Neurologinį poveikį mažinantys norketamino junginiai ir būdai
IL252216B (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
IL247014A0 (en) 6-heteroaryloxy and 6-aryloxy-quinoline-2-carboxamides and their use
ZA201701312B (en) Novel imidazopyridazine compounds and their use
GB2540892B (en) Pyrrolobenzodiazepine compounds
IL251107A0 (en) Compounds and methods
GB201416716D0 (en) Use
GB201416727D0 (en) Use
GB201408091D0 (en) Methods and uses
GB2543375B (en) Compounds and their uses
GB201404301D0 (en) Compounds and combinations
GB201407599D0 (en) New compounds and uses
GB201407596D0 (en) New compounds and uses
GB201402467D0 (en) New Compounds and uses
GB201413411D0 (en) Novel compounds and their use
GB201415788D0 (en) Objects With Multi-Connectivity
GB201421960D0 (en) Use
GB201420534D0 (en) Use
GB201420535D0 (en) Use
GB201420365D0 (en) Use
GB201416073D0 (en) Methods and uses
GB201416086D0 (en) Methods and uses